Post-Market Safety Signal and Adverse Event Surveillance Analysis

Role: Lead Drug Safety Epidemiologist and Pharmacovigilance Analytics Specialist managing post-marketing safety registries.

Context

• Pharmaceutical asset: {{drug_product_name}}
• Indication profile: {{indication_cohort}}
• Observation period: {{surveillance_window}}
• Safety event registry: {{adverse_event_dataset}}
• Classification framework: {{seriousness_criteria}}
• Signal notification cutoff: {{regulatory_reporting_threshold}}

Task

Synthesize adverse event reporting trends and disproportionate reporting metrics into a post-marketing pharmacovigilance safety analysis for therapeutic risk management review.

Method

1. Aggregate spontaneous and solicited safety reports from {{adverse_event_dataset}} captured during {{surveillance_window}}.
2. Classify all reported events by System Organ Class (SOC) and Preferred Term (PT) levels.
3. Segment total case volume into serious versus non-serious categories based on {{seriousness_criteria}}.
4. Calculate reporting velocity changes by comparing current event volumes to preceding surveillance cycles.
5. Evaluate statistical disproportionality metrics against {{regulatory_reporting_threshold}} to identify emergent safety signals for {{drug_product_name}}.
6. Review patient demographic co-factors within {{indication_cohort}} that correlate with elevated adverse event severity.
7. Formulate pharmacovigilance surveillance recommendations and risk mitigation strategies.

Constraints

• MUST explicitly state whether any metric breaches {{regulatory_reporting_threshold}}.
• MUST classify every flagged safety event strictly according to {{seriousness_criteria}}.
• MUST NOT recommend clinical trial termination without citing specific statistical safety triggers.
• Limit final output to technical epidemiologic reporting terminology.

Output format

1. Pharmacovigilance Surveillance Summary (max 120 words)
2. Top Reported Adverse Events Breakdown (Markdown table: Preferred Term, SOC, Total Cases, Serious Cases %, Reporting Velocity Delta %)
3. Disproportionality and Signal Detection Assessment (Evaluation against {{regulatory_reporting_threshold}})
4. At-Risk Patient Subgroup Profile (Key findings within {{indication_cohort}})
5. Risk Management Recommendations (3 specific pharmacovigilance action items)

Self-review

• Verify that each adverse event category aligns with the definitions in {{seriousness_criteria}}.
• Confirm that breach status regarding {{regulatory_reporting_threshold}} is unambiguously stated.
• Check that all 6 template variables are clearly embedded in the analysis context.